B

Baroness Merron (Lab)

Speaking in the House of Lords on 19 November 2026

Debate

Alzheimer’s Disease and Vascular Dementia

Contribution

The noble Lord is quite right. I do not think it is granular; it is key to any care plan. I would expect that to go on even now as part of the prescribing process. People living with dementia will be among the first to benefit from that investment into GPs, to ensure that the care plans are up to date—to the point that the noble Lord has just raised. From next year, every ICB will be required to commission a care management service, starting with those at the highest risk and expanding over time. I turn to research and treatments—on the points and areas of detail that I have not been able to cover, I will be very pleased to write to noble Lords. We are investing in dementia research across all areas, from cause, diagnosis and prevention to treatment, care and support, including for carers. I am glad that the noble Baroness, Lady Bottomley, and the noble Lord, Lord Jackson, discussed unpaid carers—they are so key. We are assisting them, for example, through a new MyCarer section on the NHS app. It was only today that Anna Dixon MP was appointed as the champion for unpaid carers, which will also bring focus to them. I also agree with the credit paid to my noble friend Lady Pitkeathley for her efforts, which are always to be commended. The Dame Barbara Windsor Dementia Goals programme aims to realise a new generation of precision dementia therapies and solutions by accelerating innovations. We are investing £33 million in this programme to support the work of the BARBARA Alliance and its flagship project, BARBARA. That will create a single platform that will bring together the UK’s health data, research and clinical trial capabilities. This is an exciting time for dementia research. As noble Lords have said, new innovations can transform the diagnosis and treatment of dementia. I finish on this point: NICE is currently evaluating drugs for early Alzheimer’s disease. We certainly encourage any companies developing new treatments to engage with NICE and NHS England, because—to the point that the noble Baroness, Lady Barker, made—we want to support patient access to clinically and financially effective treatments. This is a topic close to many people’s hearts. It is a very personal matter for many, and I can commit, on behalf of the Government, that we will continue to work on it. I am grateful for the support, interest and challenge from noble Lords today.

More from Baroness Merron (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.